Refined sugar free, no bake chocolate and peanut butter cheesecake
This is a creamy, no-bake dessert made with a blend of raw chocolate, banana, and peanut butter, featuring a refined sugar-free and indulgent yet wholesome cheesecake-style filling.
Want to make this later? Tap on the bookmark ribbon at the top of your screen and come back to it when you need to shop for ingredients or start cooking.
Ingredients
Crust
3/4cup - oats — rolled
2/3cup - desiccated coconut
1/2cup - dates — Medjool, pitted
1/4cup - macadamia nuts
2Tbs - water
Filling
1 1/2cup - bananas — chopped
1/2 - avocado — large
2Tbs - sugar free peanut butter — extra
2Tbs - coconut oil — melted
1Tbs - cocoa powder
Method
For the crust, place everything in a food processor and blend until smooth. Grease an 18cm loose-bottom cake tin with some cooking spray.
Press the mixture into the tin to form an even layer.
For the filling, place everything in a food processor and blend until smooth.
Spread this over the crust and smooth it out.
Add a tablespoon or two of peanut butter on top of the cheesecake and ripple it in using the tip of a small knife.
Refrigerate for at least 2 hours or overnight before serving in slices.
Tip: You can garnish the cheesecake with salted peanuts, macadamias or edible flowers, if you prefer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
an hour ago
- News24
Kempton Park teen's amazing recovery after glass slices through his abdomen in freak accident
Supplied Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
News24
2 hours ago
- News24
Joshua Jackson in custody battle with his ex-wife over daughter's schooling
The ink has barely dried on Joshua Jackson and Jodie Turner-Smith's divorce papers, and already the exes are locked in a bitter legal dispute over their shared parenting arrangement. The Doctor Odyssey star has filed an emergency custody review, claiming his ex-wife enrolled their five-year-old daughter, Juno, in a new school without his consent. In the documents, obtained by People magazine, Joshua (46) alleges that Jodie (38) believes, 'it's no big deal to force Juno to start over with a new school'. He also complains that the new school is 45 minutes away from his home, making regular drop-offs and pick-ups nearly impossible for him. However, Joshua's concern goes beyond the school change itself. 'Jodie is attempting to create a scenario where Juno travels with her rather than attending a traditional school,' he claims. The Dawson's Creek star wants the court to order that their daughter remains in her current school in Calabasas, in Los Angeles, for the upcoming academic year. He also wants it stipulated that both parents must agree before any future school changes can be made. View this post on Instagram A post shared by THE AGENCY: CENTRAL INTELLIGENCE (@theagency_sho) Joshua and Jodie met at a 2018 party hosted by R&B singer Usher. They married in secret a year later before welcoming Juno in April 2020. In October 2023, the British model and actress filed for divorce on the grounds of 'irreconcilable differences'. Joshua recently told USA Today that he believes Jodie is attempting to change their daughter's schooling so there is more flexibility for Juno to accompany her when she needs to travel for work. READ MORE| 'I don't think of it as a failure' – Jodie Turner-Smith on divorcing Joshua Jackson He says he thinks maintaining educational stability is important for their daughter's well-being during her formative years – something he didn't experience as a child actor. 'I started acting at a young age. I have spent a lot of time with on-set or on-location tutors,' he said. 'Even in the best case, it cannot begin to provide a child with the same nurturing and enrichment, peer relationships and social skills that a classroom and school community environment provides.' He added that Juno has already endured a lot of changes, from their divorce to her home burning down during the LA wildfires in January, so she doesn't need any more turmoil. 'Unnecessary school change cannot be in her interests.' Jodie is yet to speak publicly on the matter. Despite their legal woes, it seems they're both moving on with their lives. View this post on Instagram A post shared by Joshua Jackson (@vancityjax) Jodie currently stars in The Agency as Dr Sami Zahir, an academic who becomes romantically involved with an undercover CIA agent. Describing her role she says, 'I love playing a dark-skinned Sudanese woman speaking Arabic on this show. I believe it's one of the most beautiful languages on this planet and I hope that Arabic-speaking people feel represented.' She is also set to be filming in London throughout next year. Meanwhile, Joshua is gearing up to return to his home in LA, which had to be rebuilt after being destroyed in the wildfires.
Yahoo
2 hours ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
